Advanced Management Strategies in Severe Asthma and COPD (MC)-Rapid fire Questions in Asthma Khurana

Rapid fire Questions in Asthma Khurana

Pdf Summary

The document appears to be a series of audience response system (ARS) questions from a master class on advanced management strategies for severe asthma and COPD, led by Dr. Sandhya Khurana. Below is a summary of the key points discussed through these questions.<br /><br />Participants are asked to self-rate their alertness and provide some background information regarding their specialties and years in practice. The target audience includes specialists in practice, fellows in training, specialty advanced practice providers (APPs), and industry colleagues, focusing on pulmonary, allergy, or airways diseases like COPD and asthma.<br /><br />Questions are centered around the understanding and management of severe asthma, including the prevalence of severe asthma amongst asthma patients, which is queried at different percentages.<br /><br />The biologic treatments and their mechanisms are a significant focus. Participants are tested on their knowledge about T2 cytokines, such as IL-5, IL-8, IL-4, and IL-13, with a specific question identifying IL-8 as not being a T2 cytokine. The quiz also delves into the percentage of severe asthma patients who have T2-low asthma and asks about the biologic therapies that induce eosinophil depletion via antibody-dependent cell cytotoxicity (ADCC).<br /><br />Questions are also raised about the efficacy of various biologics in reducing oral corticosteroid (OCS) use in randomized controlled trials (RCTs), with Dupilumab, Tezepelumab, Omalizumab, and Benralizumab being mentioned. Additionally, treatment response predictability using elevated FeNO levels for certain biologics is examined.<br /><br />Finally, the dosing criteria of biologics are covered, focusing on which biologic requires weight-based dosing—specifically Reslizumab—and which biologic has observed treatment-emergent eosinophilia, highlighting Dupilumab.<br /><br />Overall, this master class seems to target healthcare professionals involved in the respiratory specialty, emphasizing the latest biologic therapies and management strategies for severe asthma.

Keywords

severe asthma

COPD

Chronic Obstructive Pulmonary Disease

biologic treatments

T2 cytokines

eosinophil depletion

oral corticosteroid reduction

FeNO levels

weight-based dosing

treatment-emergent eosinophilia

respiratory specialty

COPD

Chronic Obstructive Pulmonary Disease